Edmonson H.A. Differential diagnosis of tumors and tumor – like lesion of liver in infancy and childhood. AMA Am Arch Dis Child. 1956;91(2):168– 186. doi: 10.1001/archpedi.1956.02060020170015..
DOI: 10.1001/archpedi.1956.02060020170015
Craig J.R., Peters R.L., Edmondson H.A. Omata M. Fibrolamel – lar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinicopathologic features. Cancer. 1980;46(2):372–379. doi: 10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s..
DOI: 10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s
Berman M.M., Libbey P., Foster J.H. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma–an atypical variant with a favorable prognosis. Cancer. 1980;46(6):1148–1155. doi: 10.1002/1097-0142(19800915)46:6<1448::aid-cncr2820460626>3.0.co;2-j..
DOI: 10.1002/1097-0142(19800915)46:6<1448::aid-cncr2820460626>3.0.co;2-j
Ringe B., Wittekind C., Weimann A., Tusch G., Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992;175(4):299–305. Available at: https://pubmed.ncbi.nlm.nih.gov/1329242/.https://pubmed.ncbi.nlm.nih.gov/1329242/
Ringe B., Wittekind C., Weimann A., Tusch G., Pichlmayr R. Results of hepatic resection and transplantation for fibrolamellar carcinoma. Surg Gynecol Obstet. 1992;175(4):299–305. Available at: https://pubmed.ncbi.nlm.nih.gov/1329242/.https://pubmed.ncbi.nlm.nih.gov/1329242/
Pinna A.D., Iwatsuki S., Lee R.G., Todo S., Madariaga J.R., Marsh J.W. et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy of transplantation. Hepatology. 1997;26(4):877–83. doi: 10.1002/hep.510260412..
DOI: 10.1002/hep.510260412
El-Gazzaz G., Wong W., El-Hadary M.K., Gunson B.K., Mirza D.F., Mayer A.D. et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13(1 Suppl.):S406–S409. Available at: https://pubmed.ncbi.nlm.nih.gov/11112043/https://pubmed.ncbi.nlm.nih.gov/11112043/
El-Gazzaz G., Wong W., El-Hadary M.K., Gunson B.K., Mirza D.F., Mayer A.D. et al. Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma. Transpl Int. 2000;13(1 Suppl.):S406–S409. Available at: https://pubmed.ncbi.nlm.nih.gov/11112043/https://pubmed.ncbi.nlm.nih.gov/11112043/
El-Serag H.B., Davila J.A. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803. doi: 10.1002/hep.20096..
DOI: 10.1002/hep.20096
Moreno-Luna L.E., Arrieta O., García-Leiva J., Мartínez В., Torre А., Uribe М., León-Rodríguez E. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer. 2005;5:142. doi: 10.1186/1471-2407-5-142..
DOI: 10.1186/1471-2407-5-142
Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D’Angelica M, Abou-Alfa G, Blumgart LH, DeMatteo RP. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006 Mar 15;106(6):1331-8. doi: 10.1002/cncr.21703. PMID: 16475212. doi: 10.1002/cncr.21703..
DOI: 10.1002/cncr.21703
Kaseb А.О., Shama М., Sahin I.H., Nooka А., Hassabo H.M., Vauthey J.-N. et al. Prognostic indicators and treatment outcome in 94 cases of fibrolamellar hepatocellular carcinoma. Oncology. 2013;85(4):197–203. doi: 10.1159/000354698..
DOI: 10.1159/000354698
Cronin K.A., Ries L.A., Edwards B.K. The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute. Cancer. 2014;120(S23):S3755–S3757. doi: 10.1002/cncr.29049..
DOI: 10.1002/cncr.29049
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные ново образования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf
Каприн А.Д., Старинский В.В., Петрова Г.В. (ред.). Злокачественные ново образования в России в 2017 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; 2018. Режим доступа: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.http://www.oncology.ru/service/statistics/malig-
Mavros M.N., Mayo S.C., Hyder O., Pawlik T.M. A systematic review: Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):820–830. doi: 10.1016/j.jamcoll- surg.2012.08.001..
DOI: 10.1016/j.jamcoll- surg.2012.08.001
Hemming A.W., Langer B., Sheiner P., Greig P.D., Taylor B.R. Aggressive surgical management of f ibrolamellar hepatocellular carcinoma. J Gastrointest Surg. 1997;1(4):342–346. doi: 10.1016/s1091-255x(97)80055-8..
DOI: 10.1016/s1091-255x(97)80055-8
Алиева С.Б., Бредер В.В. и др. Клинические рекомендации АОР 2019 г. Рак печени (гепатоцеллюлярный). Режим доступа: https://oncology-association.ru/files/new-clinical-guidelines/rak_pecheni.pdf.https://oncology-association.ru/files/new-clinical-guidelines/rak_pecheni.pdf
Алиева С.Б., Бредер В.В. и др. Клинические рекомендации АОР 2019 г. Рак печени (гепатоцеллюлярный). Режим доступа: https://oncology-association.ru/files/new-clinical-guidelines/rak_pecheni.pdf.https://oncology-association.ru/files/new-clinical-guidelines/rak_pecheni.pdf
Greene F.L., Sobin L.H. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin. 2008;58(3):180–190. doi: 10.3322/CA.2008.0001..
DOI: 10.3322/CA.2008.0001
Amin M.B., Greene F.L., Edge S.B., Compton C.C., Gershenwald J.E., Brookland R.K. et.al The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more «personalized» approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi: 10.3322/caac.21388..
DOI: 10.3322/caac.21388
Eggert T., McGlynn K.A., Duffy A., Manns M.P., Greten T.F., Altekruse S.F. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the surveillance, epidemiology, and end results database. United European Gastroenterol J. 2013;1(5):351–357. doi: 10.1177/2050640613501507..
DOI: 10.1177/2050640613501507
Lee C.W., Chan K.M., Lee C.F., Yu M.C., Lee W.C., Wu T.J., Chen M.F. Hepatic resection for hepatocellular carcinoma with lymph node metastasis: clinicopathological analysis and survival outcome. Asian J Surg. 2011;34(2):53–62. doi: 10.1016/S1015-9584(11)60020-1..
DOI: 10.1016/S1015-9584(11)60020-1
Watanabe J., Nakashima O., Kojiro M. Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. Jpn J Clin Oncol. 1994;24(1):37–41. Available at: https://pubmed.ncbi.nlm.nih.gov/8126919/.https://pubmed.ncbi.nlm.nih.gov/8126919/
Watanabe J., Nakashima O., Kojiro M. Clinicopathologic study on lymph node metastasis of hepatocellular carcinoma: a retrospective study of 660 consecutive autopsy cases. Jpn J Clin Oncol. 1994;24(1):37–41. Available at: https://pubmed.ncbi.nlm.nih.gov/8126919/.https://pubmed.ncbi.nlm.nih.gov/8126919/
Liu S., Chan K.W., Wang B., Qiao L. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009;104(10):2617–2625. Available at: https://pubmed.ncbi.nlm.nih.gov/19638962/https://pubmed.ncbi.nlm.nih.gov/19638962/
Liu S., Chan K.W., Wang B., Qiao L. Fibrolamellar hepatocellular carcinoma. Am J Gastroenterol. 2009;104(10):2617–2625. Available at: https://pubmed.ncbi.nlm.nih.gov/19638962/https://pubmed.ncbi.nlm.nih.gov/19638962/
Pérez-Guillermo M., Masgrau N.A., García-Solano J., Sola-Pérez J., de Agustín y de Agustín P. Cytologic aspect of fibrolamellar hepatocellular carcinoma in fine-needle aspirates. Diagn Cytopathol. 1999;21(3):180–187. doi: 10.1002/(sici)1097-0339(199909)21:3<180::aid-dc7>3.0.co;2-o..
DOI: 10.1002/(sici)1097-0339(199909)21:3<180::aid-dc7>3.0.co;2-o
Torbenson M.S. Review of the Clinicopathologic Features of Fibrolamellar Carcinoma. Adv Anat Pathol. 2007;14:217–223. doi: 10.1097/PAP.0b013e3180504913..
DOI: 10.1097/PAP.0b013e3180504913
Torbenson M.S. Morphologic Subtypes of Hepatocellular Carcinoma, Gastroenterol. Clin N Am. 2017;46(2):365–391. doi: 10.1016/j.gtc.2017.01.009..
DOI: 10.1016/j.gtc.2017.01.009
Kitabayashi К., Yokoi М., Ueno K.-I., Saito H., Takashima S., Kurose N., Nojima T. Fibrolamellar hepatocellular carcinoma: report of a case. Hepatogastroenterology. 2003;50(54):1886–1888. Available at: https://pubmed.ncbi.nlm.nih.gov/14696425/.https://pubmed.ncbi.nlm.nih.gov/14696425/
Kitabayashi К., Yokoi М., Ueno K.-I., Saito H., Takashima S., Kurose N., Nojima T. Fibrolamellar hepatocellular carcinoma: report of a case. Hepatogastroenterology. 2003;50(54):1886–1888. Available at: https://pubmed.ncbi.nlm.nih.gov/14696425/.https://pubmed.ncbi.nlm.nih.gov/14696425/
Chaudhari V.A., Khobragade K., Bhandare M., Shailesh V. Shrikhande. Management of fibrolamellar hepatocellular carcinoma. Chinese Clinical Oncology. 2018;7(5):51. doi: 10.21037/cco.2018.08.08..
DOI: 10.21037/cco.2018.08.08
Ward S.C., Huang J., Tickoo S.K., Thung S.N., Ladanyi M., Klimstra D.S. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol. 2010;23(9):1180–1190. doi: 10.1038/modpathol.2010.105..
DOI: 10.1038/modpathol.2010.105
de Boer C.J., van Krieken J.H.J.M., Janssen-van Rhijn C.M., Litvinov S.V. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol. 1999;188(2):201–206. doi: 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8..
DOI: 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8
Gires O. EpCAM in hepatocytes and their progenitors. J Hepatol. 2012:56(2):490–492. doi: 10.1016/j.jhep.2011.05.036..
DOI: 10.1016/j.jhep.2011.05.036
Sergi C.M. Hepatocellular Carcinoma, Fibrolamellar Variant: Diagnostic Pathologic Criteria and Molecular Pathology Update. A Primer Diagnostics. 2015;6(1):3. doi: 10.3390/diagnostics6010003..
DOI: 10.3390/diagnostics6010003
Graham R.P., Torbenson M.S. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings. Semin Diagn Pathol. 2017;34(2):146–152. doi: 10.1053/j.semdp.2016.12.010..
DOI: 10.1053/j.semdp.2016.12.010
Honeyman J.N., Simon E.P., Robine N., Chiaroni-Clarke R., Darcy D.G., Lim I.I. et al. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma. Science. 2014;343(6174):1010–1014. doi: 10.1126/science.1249484..
DOI: 10.1126/science.1249484
N. Graham R.P., Jin L., Knutson D.L., Kloft-Nelson S.M., Greipp P.T., Waldburger et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Modern Pathology. 2015;28(6):822–829. doi: 10.1038/modpathol.2015.4..
DOI: 10.1038/modpathol.2015.4
Dinh T.A., Vitucci E.C.M, Wauthier E., Graham R.P., Pitman W.A., Oikawa Т. et al. Comprehensive analysis of The Cancer Genome Atlas reveals a unique gene and non-coding RNA signature of fibrolamellar carcinoma. Sci Rep. 2017;7:44653. doi: 10.1038/srep44653..
DOI: 10.1038/srep44653
Vivekanandan P., Micchelli S.T., Torbenson M. Anterior gradient-2 is overexpressed by fibrolamellar carcinomas. Hum Pathol. 2009;40(3):293–299. doi: 10.1016/j.humpath.2008.08.003..
DOI: 10.1016/j.humpath.2008.08.003
Simon E.P., Freije C.A., Farber B.A., Lalazar G., Darcy D.G., Honeyman J.N. et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci. 2015;112(44):E5916–E5925. doi: 10.1073/pnas.1424894112..
DOI: 10.1073/pnas.1424894112
Simon E.P., Freije C.A., Farber B.A., Lalazar G., Darcy D.G., Honeyman J.N. et al. Transcriptomic characterization of fibrolamellar hepatocellular carcinoma. Proc Natl Acad Sci. 2015;112(44):E5916–E5925. doi: 10.1073/pnas.1424894112..
DOI: 10.1073/ pnas.1424894112
Orsatti G., Hytiroglou P., Thung S.N., Ishak K.G., Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver. 1997;17(3):152–156. doi: 10.1111/j.1600-0676.1997.tb00798.x..
DOI: 10.1111/j.1600-0676.1997.tb00798.x
Orsatti G., Hytiroglou P., Thung S.N., Ishak K.G., Paronetto F. Lamellar fibrosis in the fibrolamellar variant of hepatocellular carcinoma: a role for transforming growth factor beta. Liver. 1997;17(3):152–156. doi: 10.1111/j.1600-0676.1997.tb00798.x..
DOI: 10.1111/ j.1600-0676.1997.tb00798.x
Buckley A.F., Burgart L.J., Kakar S. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma. Hum Pathol. 2006;37(4):410–414. doi: 10.1016/j.humpath.2005.12.009..
DOI: 10.1016/j.humpath.2005.12.009
Kannangai R., Sahin F., Torbenson M.S. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod Pathol. 2006;19:1456–1461. doi: 10.1038/modpathol.3800665..
DOI: 10.1038/modpathol.3800665
Kannangai R., Vivekanandan Р., Martinez-Murillo F., Choti M., Torbenson M. Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Hum Pathol. 2007;38(4):639–644. doi: 10.1016/j.humpath.2006.07.019..
DOI: 10.1016/j.humpath.2006.07.019
Torbenson M., Kannangai R., Abraham S., Sahin F., Choti M., Wang J. Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in human hepatocellular carcinoma. Am J Clin Pathol. 2004;122(3):377–382. doi: 10.1309/YH0H-3FKY-M4RM-U1JF..
DOI: 10.1309/YH0H-3FKY-M4RM-U1JF
Sorenson E.C., Khanin R., Bamboat Z.M., Cavnar M.J., Kim T.S. et al. Genome and transcriptome profiling of fibrolamellar hepatocellular carcinoma demonstrates p53 and IGF2BP1 dysregulation. PLoS One. 2017;12(5):0176562. doi: 10.1371/journal.pone.0176562..
DOI: 10.1371/journal.pone.0176562
Darcy D.G., Malek M.M., Kobos R., Klimstra D.S., DeMatteo R., La Quaglia M.P. Prognostic factors in fibrolamellar hepatocellular carcinoma in young adults. J Pediatr Surg. 2015;50(1):153–156. doi: 10.1016/j.jpedsurg.2014.10.039..
DOI: 10.1016/j.jpedsurg.2014.10.039
Ang C.S., Kelley R.K., Choti M.A., Cosgrove D.P., Chou J.F., Klimstra D. et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6(1):3–9. Available at: https://pubmed.ncbi.nlm.nih.gov/23505572/https://pubmed.ncbi.nlm.nih.gov/23505572/
Ang C.S., Kelley R.K., Choti M.A., Cosgrove D.P., Chou J.F., Klimstra D. et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6(1):3–9. Available at: https://pubmed.ncbi.nlm.nih.gov/23505572/https://pubmed.ncbi.nlm.nih.gov/23505572/
Dahan M.H., Kastell P. Fibrolamellar hepatic carcinoma with a presentation similar to that of septic pregnancy. A case report. J Reprod Med. 2002;47(1):47–49. Available at: https://www.pubfacts.com/detail/11838311/Fibrolamellar-hepatic-carcinoma-with-a-presentation-similar-to-that-of-septic-pregnancy-A-case-repor.https://www.pubfacts.com/detail/11838311/Fibrolamellar-hepatic-carcinoma-with-a-presentation-similar-to-that-of-septic-pregnancy-A-case-repor
Dahan M.H., Kastell P. Fibrolamellar hepatic carcinoma with a presentation similar to that of septic pregnancy. A case report. J Reprod Med. 2002;47(1):47–49. Available at: https://www.pubfacts.com/detail/11838311/Fibrolamellar-hepatic-carcinoma-with-a-presentation-similar-to-that-of-septic-pregnancy-A-case-repor.https://www.pubfacts.com/detail/11838311/Fibrolamellar-hepatic-carcinoma-with-a-presentation-similar-to-that-of-septic-pregnancy-A-case-repor
Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica. 2012;2012:743790. doi: 10.6064/2012/743790..
DOI: 10.6064/2012/743790
Lloreta J., Vadell C., Fabregat X., Serrano S. Fibrolamellar hepatic tumor with neurosecretory features and systemic deposition of AA amyloid. Ultrastruct Pathol. 1994;18(1–2):287–292. doi: 10.3109/01913129409016302..
DOI: 10.3109/01913129409016302
Friedman A.C., Lichtenstein J.E., Goodman Z., Fishman E.K., Siegelman S.S., Dachman A.H. Fibrolamellar hepatocellular carcinoma. Radiology. 1985;157(3):583–587. doi: 10.1148/radiology.157.3.2997835..
DOI: 10.1148/radiology.157.3.2997835
Ichikawa T., Federle M.P., Grazioli L., Madariaga J., Nalesnik M., Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology. 1999;213(2):352–361. doi: 10.1148/radiology.213.2.r99nv31352..
DOI: 10.1148/radiology.213.2.r99nv31352
Brandt D.J., Johnson C.D., Stephens D.H., Weiland L.H. Imaging of fibrolamellar hepatocellular carcinoma. AJR Am J Roentgenol. 1988;151(2):295–299. doi: 10.2214/ajr.151.2.295..
DOI: 10.2214/ajr.151.2.295
Kadoya M., Matsui O., Takashima T., Nonomura A. Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology. 1992;183(3):819–825. doi: 10.1148/radiology.183.3.1316622..
DOI: 10.1148/radiology.183.3.1316622
Ringe K.I., Husarik D.B., Sirlin C.B., Merkle E.M. Gadoxetate disodiumenhanced MRI of the liver. Part 1, Protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol. 2010;195(1):13–28. doi: 10.2214/AJR.10.4392..
DOI: 10.2214/AJR.10.4392
Palm V., Sheng R., Mayer P., Weiss K.H., Springfeld C., Mehrabi A. et al. Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI. Cancer Imaging. 2018;18:9. doi: 10.1186/s40644-018- 0143-y..
DOI: 10.1186/s40644-018- 0143-y
Badiee S., Franc B.L., Webb E.M., Chu B., Hawkins R.A., Coakley F. Role of IV iodinated contrastmaterial in 18F-FDG PET/CT of liver metastases. AJR Am J Roentgenol. 2008;191(5):1436–1439. doi: 10.2214/AJR.07.3750..
DOI: 10.2214/AJR.07.3750
Mayo S.C., Mavros M.N., Nathan H., Cosgrove D., Herman J.M., Kamel I. et al. Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg. 2014;218(2):196–205. doi: 10.1016/j.jamcollsurg.2013.10.011..
DOI: 10.1016/j.jamcollsurg.2013.10.011
McAteer J.P., Goldin A.B., Healey P.J., Gow K.W. Hepatocellular carcinoma in children: epidemiology and the impact of regional lymphadenectomy on surgical outcomes. J Pediatr Surg. 2013;48(11):2194–2201. doi: 10.1016/j.jpedsurg.2013.05.007..
DOI: 10.1016/j.jpedsurg.2013.05.007
Amini N., Ejaz A., Spolverato G., Maithel S.K., Kim Y., Pawlik T.M. Management of lymph nodes during resection of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a systematic review. J Gastrointest Surg. 2014;18(12):2136–2148. doi: 10.1007/s11605-014-2667-1..
DOI: 10.1007/s11605-014-2667-1
Yamashita S., Vauthey J.N., Kaseb A.O., Aloia T.A., Conrad C., Hassan M.M. et al. Prognosis of Fibrolamellar Carcinoma Compared to Non-cirrhotic Conventional Hepatocellular Carcinoma. J Gastrointest Surg. 2016;20(10):1725–1731. doi: 10.1007/s11605-016-3216-x..
DOI: 10.1007/s11605-016-3216-x
Njei B., Konjeti V.R., Ditah I. Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointest Cancer Res. 2014;7(2):49–54. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007676/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007676/
Njei B., Konjeti V.R., Ditah I. Prognosis of Patients With Fibrolamellar Hepatocellular Carcinoma Versus Conventional Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Gastrointest Cancer Res. 2014;7(2):49–54. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007676/.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007676/
Fouzas I., Sotiropoulos G.C., Molmenti E.P., Beckebaum S., Schmitz K.J., Broelsch C.E. et al. «Preemptive» live donor liver transplantation for fibrolamellar hepatocellular carcinoma: A case report. Transplant Proc. 2008;40(10):3806–3807. doi: 10.1016/j.transproceed.2008.09.050..
DOI: 10.1016/j.transproceed.2008.09.050
Atienza L.G., Berger J., Mei X., Shah M.B., Daily M.F., Grigorian A., Gedaly R. Liver transplantation for fibrolamellar hepatocellular carcinoma: A national perspective. J Surg Oncol. 2017;115(3):319–323. doi: 10.1002/jso.24515..
DOI: 10.1002/jso.24515
Peacock J.G., Call J.A., Olivier K.R. Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma. Rare Tumors. 2013;5(3):e28. doi: 10.4081/rt.2013.e28..
DOI: 10.4081/rt.2013.e28
Mafeld S., French J., Tiniakos D., Haugk B., Manas D., Littler P. Fibrolamellar hepatocellular carcinoma: treatment with yttrium-90 and subsequent surgical resection. Cardiovasc Intervent Radiol. 2018;41(5):816–820. doi: 10.1007/s00270-018-1903-6..
DOI: 10.1007/s00270-018-1903-6
Czauderna P., Zbrzezniak G., Narozanski W., Korzon M., Wyszomirska M., Stoba C. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer. 2006;46(7):825–828. Available at: https://pubmed.ncbi.nlm.nih.gov/16123986/.https://pubmed.ncbi.nlm.nih.gov/16123986/
Czauderna P., Zbrzezniak G., Narozanski W., Korzon M., Wyszomirska M., Stoba C. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer. 2006;46(7):825–828. Available at: https://pubmed.ncbi.nlm.nih.gov/16123986/.https://pubmed.ncbi.nlm.nih.gov/16123986/
Fonseca G.M., Varella A.D., Coelho F.F., Abe E.S., Dumarco R.B., Herman P. Fibrolamellar hepatocellular carcinoma downstaging. World J Gastrointest Surg. 2014;6(6):107–111. doi: 10.4240/wjgs.v6.i6.107..
DOI: 10.4240/wjgs.v6.i6.107
Chakrabarti S., Tella S.H., Kommalapati A., Huffman B.M., Yadav S., Riaz I.B. et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019;10(3):554–561. doi: 10.21037/jgo.2019.01.35..
DOI: 10.21037/jgo.2019.01.35
Patt Y.Z., Hassan M.M., Lozano R.D., Brown T.D., Vauthey J.N., Curley S.A., Ellis L.M. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003;21(3):421–427. doi: 10.1200/JCO.2003.10.103..
DOI: 10.1200/JCO.2003.10.103
Weeda V.B., Murawski M., McCabe A.J., Maibach R., Brugières L., Roebuck D. et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – results and treatment recommendations from the Childhood Liver Tumour Strategy Group (SIOPEL) experience. Eur J Cancer. 2013;49(12):2698–2704. doi: 10.1016/j.ejca.2013.04.012..
DOI: 10.1016/j.ejca.2013.04.012
Gras P., Truant S., Boige V., Ladrat L., Rougier P., Pruvot F.R., Hebbar M. Prolonged Complete Response after GEMOX chemotherapy in a Patient with Advanced Fibrolamellar Hepatocellular Carcinoma. Case Rep Oncol. 2012;5(1):169–172. doi: 10.1159/000338242..
DOI: 10.1159/000338242
Riehle K.J., Yeh M.M., Yu J.J., Kenerson H.L., Harris W.P., Park J.O., Yeung R.S. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. Mod Pathol. 2015;28(1):103–110. doi: 10.1038/modpathol.2014.78..
DOI: 10.1038/modpathol.2014.78
Benito V., Segura J., Martínez M.S., Arencibia O., Lubrano A. Fibrolamellar Hepatocellular Carcinoma Metastatic to the Ovary. Obstet Gynaecol. 2012;32(2):200–202. doi: 10.3109/01443615.2011.621558..
DOI: 10.3109/01443615.2011.621558
Nowak A.K., Findlay M., Culjak G., Stockler M.R. Tamoxifen for hepatocellular carcinoma. Cochrane Database Syst Rev. 2020;(8):CD001024. doi: 10.1002/14651858..
DOI: 10.1002/14651858
Bauer U., Mogler C., Braren R.F., Algül H., Schmid R.M., Ehmer U. Progression after Immunotherapy for Fibrolamellar Carcinoma. Visc Med. 2019;35(1):39–42. doi: 10.1159/000497464..
DOI: 10.1159/000497464